Holen Sie sich die Stockscreener-App
1.655
2.65%
-0.045
Schlusskurs vom Vortag:
$1.70
Offen:
$1.67
24-Stunden-Volumen:
1.05M
Relative Volume:
0.66
Marktkapitalisierung:
$318.04M
Einnahmen:
$199.19M
Nettoeinkommen (Verlust:
$-16.02M
KGV:
-19.54
EPS:
-0.0847
Netto-Cashflow:
$168.00K
1W Leistung:
-14.25%
1M Leistung:
-26.12%
6M Leistung:
+34.55%
1J Leistung:
+19.06%
1-Tages-Spanne:
$1.65
$1.735
1-Wochen-Bereich:
$1.62
$1.96
52-Wochen-Spanne:
$1.12
$2.955
Cerus Corp Stock (CERS) Company Profile
Firmenname
Cerus Corp
Sektor
Branche
Telefon
(925) 288-6000
Adresse
1220 CONCORD AVENUE, CONCORD, CA
Compare CERS vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CERS
Cerus Corp
|
1.655 | 326.69M | 199.19M | -16.02M | 168.00K | -0.0847 |
|
ABT
Abbott Laboratories
|
108.06 | 187.91B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
340.56 | 129.05B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
87.43 | 112.19B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
68.66 | 101.72B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
82.12 | 49.14B | 6.07B | 1.06B | 1.34B | 1.8063 |
Cerus Corp Stock (CERS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-12 | Eingeleitet | Craig Hallum | Buy |
| 2023-01-20 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-01-17 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-06-16 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-02-26 | Eingeleitet | BTIG Research | Buy |
| 2019-11-13 | Hochstufung | BTIG Research | Neutral → Buy |
| 2019-08-28 | Eingeleitet | Stifel | Buy |
| 2019-08-23 | Fortgesetzt | Stephens | Overweight |
| 2018-01-05 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2017-12-08 | Fortgesetzt | BTIG Research | Neutral |
| 2016-07-07 | Fortgesetzt | Cantor Fitzgerald | Buy |
| 2015-12-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2014-05-02 | Bestätigt | MLV & Co | Buy |
| 2013-04-24 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-03-15 | Bestätigt | MLV & Co | Buy |
| 2012-04-17 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2012-02-29 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2011-11-10 | Bestätigt | MLV & Co | Buy |
| 2011-06-03 | Eingeleitet | Wedbush | Outperform |
| 2011-03-04 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2010-03-09 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2009-08-26 | Hochstufung | Avondale | Mkt Perform → Mkt Outperform |
Alle ansehen
Cerus Corp Aktie (CERS) Neueste Nachrichten
Greenman, Cerus Corp president, sells $156k in CERS stock By Investing.com - Investing.com Nigeria
Cerus CFO Kevin Green sells $169k in shares - Investing.com
Cerus corp chief medical officer sells shares worth $250k - Investing.com
Cerus CFO Kevin Green sells $169k in CERS stock By Investing.com - Investing.com Australia
Cerus CFO Kevin Green sells $169k in CERS stock - Investing.com Australia
Cerus (NASDAQ:CERS) CFO Kevin Dennis Green Sells 27,796 Shares - MarketBeat
Richard Benjamin Sells 61,233 Shares of Cerus (NASDAQ:CERS) Stock - MarketBeat
Cerus Corp chief medical officer sells shares worth $202k - Investing.com
Cerus Corp chief legal officer Jensen sells $61,859 in stock - Investing.com
Cerus Corp COO Jayaraman sells $68k in shares - Investing.com
Greenman, Cerus Corp president, sells $156k in CERS stock - Investing.com
Cerus Corp COO Jayaraman sells $68k in shares By Investing.com - Investing.com UK
Cerus Details INTERCEPT Growth Plan, BCA Deal Upside and 2026 RBC Milestones at TD Cowen Conference - Yahoo Finance
Cerus (NASDAQ:CERS) Stock Rating Lowered by Wall Street Zen - MarketBeat
Cathie Wood's ARK Investment Acquires Shares in Cerus (CERS) - GuruFocus
CERS Earnings History & Surprises | EPS & Revenue Results | CERUS CORP (NASDAQ:CERS) - ChartMill
Cerus Corporation (NASDAQ:CERS) Q4 2025 Earnings Call Transcript - Insider Monkey
Cerus (CERS) Revenue Growth Outpaces Market And Reinforces Bullish Margin Recovery Narrative - simplywall.st
Cerus at TD Cowen Conference: Strategic Growth in Blood Transfusion - Investing.com South Africa
$CERS stock is down 16% today. Here's what we see in our data. - Quiver Quantitative
Cerus Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
MongoDB, Surgery Partners, Harrow And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Cerus Corp (CERS) Q4 2025 Earnings Call Highlights: Record Reven - GuruFocus
Cerus Corporation 2025 Annual Report: INTERCEPT Blood System, Product Pipeline, and Regulatory Updates - Minichart
Cerus: Q4 Earnings Snapshot - theheraldreview.com
Cerus Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Cerus Q4 Earnings Call Highlights - Yahoo Finance
Cerus Corp (NASDAQ:CERS) Reports Mixed Q4 2025 Results, Stock Falls on Revenue Miss - ChartMill
Cerus: Q4 Financial Results Overview - Bitget
Earnings call transcript: Cerus Corporation Q4 2025 exceeds revenue expectations - Investing.com
Cerus (NASDAQ:CERS) Posts Quarterly Earnings Results, Hits Expectations - MarketBeat
Cerus 10-K: Revenue $233.8M, product growth drives results - TradingView
Cerus (NASDAQ: CERS) outlines INTERCEPT blood system pipeline - Stock Titan
CERS Forecasts Growth in 2026 Product Revenue - GuruFocus
Cerus Corporation (CERS) Stock Rises on Q4 2025 Earnings - Quiver Quantitative
Cerus falls 7% after posting in-line Q4 earnings, revenue beat - Investing.com South Africa
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Cerus Q4 Earnings Assessment - Benzinga
Cerus (Nasdaq: CERS) grows 2025 revenue 16% and reaffirms 2026 outlook - Stock Titan
Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results - Yahoo Finance
Cerus Q4 2025 Earnings Call Transcript - MarketBeat
Cerus (CERS) Set to Release Q4 Earnings with Modest Revenue Grow - GuruFocus
CERS PE Ratio & Valuation, Is CERS Overvalued - Intellectia AI
Cerus (NASDAQ:CERS) Stock Price Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
Cerus Corp expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Earnings Preview For Cerus - Benzinga
Live Cerus fireside chat set for TD Cowen health conference March 3 - Stock Titan
Cerus (NASDAQ:CERS) Shares Pass Above 200-Day Moving AverageShould You Sell? - MarketBeat
Cerus sets March 2 date for Q4 and full-year 2025 earnings call - Stock Titan
Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026 - Yahoo Finance
Cerus (CERS) Projected to Post Quarterly Earnings on Thursday - Defense World
Finanzdaten der Cerus Corp-Aktie (CERS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cerus Corp-Aktie (CERS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Green Kevin Dennis | Chief Financial Officer |
Mar 06 '26 |
Sale |
2.01 |
27,796 |
55,745 |
1,168,095 |
| Benjamin Richard J | Chief Medical Officer |
Mar 05 '26 |
Sale |
2.06 |
61,233 |
126,305 |
943,762 |
| Benjamin Richard J | Chief Medical Officer |
Mar 09 '26 |
Sale |
1.88 |
40,426 |
76,029 |
879,101 |
| Benjamin Richard J | Chief Medical Officer |
Mar 06 '26 |
Sale |
2.01 |
24,235 |
48,603 |
919,527 |
| Jensen Chrystal | Chief Legal Officer |
Mar 06 '26 |
Sale |
2.01 |
30,845 |
61,860 |
1,059,139 |
| Jayaraman Vivek K | Chief Operating Officer |
Mar 06 '26 |
Sale |
2.01 |
34,094 |
68,376 |
1,912,874 |
| Greenman William Mariner | President and CEO |
Mar 06 '26 |
Sale |
2.01 |
78,187 |
156,804 |
5,446,250 |
0.81%
0.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):